Therapeutics for the treatment of glaucoma

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10981951
APP PUB NO 20170002040A1
SERIAL NO

15113773

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
REGENTS OF THE UNIVERSITY OF MINNESOTA600 MCNAMARA ALUMNI CENTER 200 OAK STREET SE MINNEAPOLIS MN 55455-2020

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dosa, Peter Vadnais Heights, US 5 9
Fautsch, Michael P Rochester, US 9 8
Georg, Gunda I St. Paul, US 11 127
Walters, Michael A Minneapolis, US 13 179

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 20, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 20, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00